VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate. It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug also includes STENDRA, or avanafil.
|Headquarters||1172 Castro Street|
MOUNTAIN VIEW, CA, United States 94040-2552
|Independent Chairman of the Board||Mark Logan|
|President, Director||Peter Tam|
|Chief Executive Officer, Director||Leland Wilson|
|Chief Financial Officer, Senior Vice President - Finance and Global Corporate Development, Secretary||Timothy Morris|
|Senior Vice President, Chief Commercial Officer||Michael Miller|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||100.7M||Book Value||$2.21|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||222.2|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-2,856.47%|
*GAAP = prior to non-GAAP analyst adjusted earnings.